Integra LifeSciences Holdings
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Integra LifeSciences Holdings's revenues will wane -0.5% and EPS will contract -49.3%.
The average estimate for revenue is $195.1 million. On the bottom line, the average EPS estimate is $0.36.
Last quarter, Integra LifeSciences Holdings reported revenue of $214.4 million. GAAP reported sales were 5.4% higher than the prior-year quarter's $203.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.78. GAAP EPS of $0.45 for Q4 were 181% higher than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 64.3%, 20 basis points worse than the prior-year quarter. Operating margin was 14.0%, 140 basis points worse than the prior-year quarter. Net margin was 6.0%, 380 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $847.9 million. The average EPS estimate is $2.57.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 153 members out of 163 rating the stock outperform, and 10 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 49 give Integra LifeSciences Holdings a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $43.08.
Is Integra LifeSciences Holdings the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Integra LifeSciences Holdings to My Watchlist.